Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials

被引：0
作者：
R Iacovelli
A Altavilla
G Procopio
S Bracarda
M Santoni
S Cascinu
E Cortesi
机构：
[1] Oncology and Human Pathology,Department of Radiology
[2] Oncology Unit B,Department of Medical Oncology
[3] Sapienza University of Rome,undefined
[4] Fondazione IRCCS Istituto Nazionale dei Tumori,undefined
[5] Medical Oncology Unit 1,undefined
[6] Azienda Sanitaria USL 8,undefined
[7] Medical Oncology Unit,undefined
[8] Polytechnic University of the Marche Region,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2013年 / 16卷
关键词：
castration-resistant prostate cancer; second line; abiraterone acetate; cabazitaxel; enzalutamide; performance status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：323 / 327
页数：4
相关论文
共 50 条
[31]   The efficacy and safety of zibotentan in the treatment of castration-resistant prostate cancer: a meta-analysis [J].
Wu, Y. ;
Shao, N. ;
Shen, Z. -X. ;
Li, Q. ;
Wang, Y. ;
Li, C. ;
Ma, G. ;
Dong, J. ;
Lu, X. -J. ;
Feng, N. -H. .
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2014, 18 (21) :3291-3296
[32]   Clinical activity of abiraterone plus prednisone in docetaxel-naive and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer [J].
Lin, Guo-Wen ;
Li, Gao-Xiang ;
Dai, Bo ;
Ye, Ding-Wei ;
Kong, Yun-Yi ;
Wang, Yue ;
Shen, Yi-Jun .
ASIAN JOURNAL OF ANDROLOGY, 2019, 21 (02) :131-+
[33]   Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials [J].
Qi, Wei-Xiang ;
Fu, Shen ;
Zhang, Qing ;
Guo, Xiao-Mao .
JOURNAL OF CHEMOTHERAPY, 2015, 27 (03) :181-187
[34]   Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone [J].
Schrader, Andres Jan ;
Boegemann, Martin ;
Ohlmann, Carsten-H. ;
Schnoeller, Thomas J. ;
Krabbe, Laura-Maria ;
Hajili, Turkan ;
Jentzmik, Florian ;
Stoeckle, Michael ;
Schrader, Mark ;
Herrmann, Edwin ;
Cronauer, Marcus V. .
EUROPEAN UROLOGY, 2014, 65 (01) :30-36
[35]   A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines [J].
Wosny, Marie ;
Aeppli, Stefanie ;
Fischer, Stefanie ;
Peres, Tobias ;
Rothermundt, Christian ;
Hastings, Janna .
TARGETED ONCOLOGY, 2025,
[36]   Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis [J].
Wang, Lin ;
Paller, Channing ;
Hong, Hwanhee ;
Rosman, Lori ;
De Felice, Anthony ;
Brawley, Otis ;
Alexander, G. Caleb .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (02) :191-202
[37]   Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer [J].
Oudard, Stephane ;
Kramer, Gero ;
Caffo, Orazio ;
Creppy, Lorraine ;
Lorio, Yohan ;
Hansen, Steinbjoern ;
Holmberg, Mats ;
Rolland, Frederic ;
Machiels, Jean-Pascal ;
Krainer, Michael .
BJU INTERNATIONAL, 2015, 115 (05) :744-752
[38]   Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients [J].
Conteduca, Vincenza ;
Caffo, Orazio ;
Fratino, Lucia ;
Lo Re, Giovanni ;
Basso, Umberto ;
D'Angelo, Alessandro ;
Donini, Maddalena ;
Verderame, Francesco ;
Ratta, Raffaele ;
Procopio, Giuseppe ;
Campadelli, Enrico ;
Massari, Francesco ;
Gasparro, Donatello ;
Ermacora, Paola ;
Messina, Caterina ;
Giordano, Monica ;
Alesini, Daniele ;
Zagonel, Vittorina ;
Veccia, Antonello ;
Lolli, Cristian ;
Maines, Francesca ;
De Giorgi, Ugo .
FUTURE ONCOLOGY, 2015, 11 (21) :2881-2891
[39]   Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials [J].
Qi, Wei-Xiang ;
Shen, Zan ;
Yao, Yang .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (12) :1785-1790
[40]   Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials [J].
Wei-Xiang Qi ;
Zan Shen ;
Yang Yao .
Journal of Cancer Research and Clinical Oncology, 2011, 137 :1785-1790
12345